RISEDRONATE SODIUM (risedronate sodium) by Fosun Pharma is agent. Approved for paget's disease of bone in men, women. First approved in 2014.
Drug data last refreshed 18h ago
agent. At the cellular level, risedronate sodium inhibits osteoclasts. The osteoclasts adhere normally to the bone surface, but show evidence of reduced active resorption (for example, lack of ruffled border). Histomorphometry in rats, dogs, and minipigs showed that risedronate sodium treatment…
Worked on RISEDRONATE SODIUM at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.
Risedronate Sodium in Post Menopausal Osteoporosis